Nov 26 (Reuters) - PTC Therapeutics ( PTCT ) said on
Tuesday its drug did not meet the main goal in a mid-stage trial
evaluating it in patients with a type of fatal neurodegenerative
disease called amyotrophic lateral sclerosis.